These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 26650831)

  • 21. Breast cancer phenotype influences MRI response evaluation after neoadjuvant chemotherapy.
    Negrão EMS; Souza JA; Marques EF; Bitencourt AGV
    Eur J Radiol; 2019 Nov; 120():108701. PubMed ID: 31610321
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of
    Hunt KN; Conners AL; Goetz MP; O'Connor MK; Suman V; Kalari K; Weinshilboum R; Wang L; Carter J; McLaughlin S; Aspitia AM; Gray R; Northfelt D; Boughey JC
    AJR Am J Roentgenol; 2019 Oct; 213(4):932-943. PubMed ID: 31166752
    [No Abstract]   [Full Text] [Related]  

  • 23. Comparative accuracy of preoperative tumor size assessment on mammography, sonography, and MRI: Is the accuracy affected by breast density or cancer subtype?
    Leddy R; Irshad A; Metcalfe A; Mabalam P; Abid A; Ackerman S; Lewis M
    J Clin Ultrasound; 2016 Jan; 44(1):17-25. PubMed ID: 26294391
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of PET CT to evaluate the response to neoadjuvant chemotherapy in advanced breast cancer: comparison with ultrasonography and magnetic resonance imaging.
    Choi JH; Lim HI; Lee SK; Kim WW; Kim SM; Cho E; Ko EY; Han BK; Park YH; Ahn JS; Im YH; Lee JE; Yang JH; Nam SJ
    J Surg Oncol; 2010 Oct; 102(5):392-7. PubMed ID: 19877158
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of breast magnetic resonance imaging clinical tumor size with pathologic tumor size in patients status post-neoadjuvant chemotherapy.
    Williams M; Eatrides J; Kim J; Talwar H; Esposito N; Szabunio M; Ismail-Khan R; Kiluk J; Lee M; Laronga C; Khakpour N
    Am J Surg; 2013 Oct; 206(4):567-73. PubMed ID: 23809673
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of mammography, digital breast tomosynthesis, automated breast ultrasound, magnetic resonance imaging in evaluation of residual tumor after neoadjuvant chemotherapy.
    Park J; Chae EY; Cha JH; Shin HJ; Choi WJ; Choi YW; Kim HH
    Eur J Radiol; 2018 Nov; 108():261-268. PubMed ID: 30396666
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Magnetic resonance imaging and ultrasound for prediction of residual tumor size in early breast cancer within the ADAPT subtrials.
    Graeser M; Schrading S; Gluz O; Strobel K; Herzog C; Umutlu L; Frydrychowicz A; Rjosk-Dendorfer D; Würstlein R; Culemann R; Eulenburg C; Adams J; Nitzsche H; Prange A; Kümmel S; Grischke EM; Forstbauer H; Braun M; Potenberg J; von Schumann R; Aktas B; Kolberg-Liedtke C; Harbeck N; Kuhl CK; Nitz U
    Breast Cancer Res; 2021 Mar; 23(1):36. PubMed ID: 33736679
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ultrasound-based prediction of pathologic response to neoadjuvant chemotherapy in breast cancer patients.
    Baumgartner A; Tausch C; Hosch S; Papassotiropoulos B; Varga Z; Rageth C; Baege A
    Breast; 2018 Jun; 39():19-23. PubMed ID: 29518677
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relationship between tumour size and response to neoadjuvant chemotherapy among breast cancer patients in a tertiary center in Nigeria.
    Samuel O; Olayide A; Ganiyu R; Olufemi H; Halimat A
    Malawi Med J; 2018 Mar; 30(1):13-16. PubMed ID: 29868153
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluating the role of magnetic resonance imaging post-neoadjuvant therapy for breast cancer in the NEONAB trial.
    Murphy C; Mukaro V; Tobler R; Asher R; Gibbs E; West L; Giuffre B; Baron-Hay S; Khasraw M
    Intern Med J; 2018 Jun; 48(6):699-705. PubMed ID: 28869790
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Accuracy of MRI for estimating residual tumor size after neoadjuvant chemotherapy in locally advanced breast cancer: relation to response patterns on MRI.
    Kim HJ; Im YH; Han BK; Choi N; Lee J; Kim JH; Choi YL; Ahn JS; Nam SJ; Park YS; Choe YH; Ko YH; Yang JH
    Acta Oncol; 2007; 46(7):996-1003. PubMed ID: 17851879
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Agreement between MRI and pathologic breast tumor size after neoadjuvant chemotherapy, and comparison with alternative tests: individual patient data meta-analysis.
    Marinovich ML; Macaskill P; Irwig L; Sardanelli F; Mamounas E; von Minckwitz G; Guarneri V; Partridge SC; Wright FC; Choi JH; Bhattacharyya M; Martincich L; Yeh E; Londero V; Houssami N
    BMC Cancer; 2015 Oct; 15():662. PubMed ID: 26449630
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Accuracy of Magnetic Resonance Imaging-Guided Biopsy to Verify Breast Cancer Pathologic Complete Response After Neoadjuvant Chemotherapy: A Nonrandomized Controlled Trial.
    Sutton EJ; Braunstein LZ; El-Tamer MB; Brogi E; Hughes M; Bryce Y; Gluskin JS; Powell S; Woosley A; Tadros A; Sevilimedu V; Martinez DF; Toni L; Smelianskaia O; Nyman CG; Razavi P; Norton L; Fung MM; Sedorovich JD; Sacchini V; Morris EA
    JAMA Netw Open; 2021 Jan; 4(1):e2034045. PubMed ID: 33449096
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preoperative evaluation of residual tumor extent by three-dimensional magnetic resonance imaging in breast cancer patients treated with neoadjuvant chemotherapy.
    Akazawa K; Tamaki Y; Taguchi T; Tanji Y; Miyoshi Y; Kim SJ; Ueda S; Yanagisawa T; Sato Y; Tamura S; Noguchi S
    Breast J; 2006; 12(2):130-7. PubMed ID: 16509837
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of diffusion-weighted imaging as an adjunct to contrast-enhanced breast MRI in evaluating residual breast cancer following neoadjuvant chemotherapy.
    Hahn SY; Ko EY; Han BK; Shin JH; Ko ES
    Eur J Radiol; 2014 Feb; 83(2):283-8. PubMed ID: 24315957
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Does MRI predict pathologic tumor response in women with breast cancer undergoing preoperative chemotherapy?
    Segara D; Krop IE; Garber JE; Winer E; Harris L; Bellon JR; Birdwell R; Lester S; Lipsitz S; Iglehart JD; Golshan M
    J Surg Oncol; 2007 Nov; 96(6):474-80. PubMed ID: 17640031
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Imaging response and residual metastatic axillary lymph node disease after neoadjuvant chemotherapy for primary breast cancer.
    Hieken TJ; Boughey JC; Jones KN; Shah SS; Glazebrook KN
    Ann Surg Oncol; 2013 Oct; 20(10):3199-204. PubMed ID: 23846781
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diagnostic accuracy of MRI to evaluate tumour response and residual tumour size after neoadjuvant chemotherapy in breast cancer patients.
    Bouzón A; Acea B; Soler R; Iglesias Á; Santiago P; Mosquera J; Calvo L; Seoane-Pillado T; García A
    Radiol Oncol; 2016 Mar; 50(1):73-9. PubMed ID: 27069452
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MRI evaluation of residual breast cancer after neoadjuvant chemotherapy: influence of patient, tumor and chemotherapy characteristics on the correlation with pathological response.
    Diguisto C; Ouldamer L; Arbion F; Vildé A; Body G
    Anticancer Res; 2015 Jan; 35(1):581-5. PubMed ID: 25550606
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Prospective study on the role of MRI and B ultrasonography in evaluating the tumor response to neoadjuvant chemotherapy in breast cancer].
    Ye JM; Xu L; Wang DM; Zhao JX; Zhang LB; Duan XN; Liu YH
    Zhonghua Wai Ke Za Zhi; 2009 Mar; 47(5):349-52. PubMed ID: 19595011
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.